Researchers from the University of Illinois Urbana-Champaign have identified a protein, FGD3, that can predict which breast cancer patients will respond well to chemotherapy and immunotherapy. The discovery, based on genome-wide screening in human cancer cells, suggests that FGD3 may serve as a promising biomarker for treatment efficacy, according to a press release.
The study's findings could have significant implications for personalized cancer care. By testing for FGD3 levels, oncologists might be able to tailor treatment plans, avoiding ineffective therapies and their side effects for patients unlikely to benefit. This approach aligns with the broader trend toward precision medicine in oncology.
For companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), which focuses on developing novel immunotherapies, such biomarkers are critical. They can help identify patient populations most likely to respond to specific immunotherapies, potentially accelerating clinical development and improving outcomes.
The research team conducted genome-wide screening in human cancer cell lines to identify genes associated with sensitivity to chemotherapy and immunotherapy. They discovered that FGD3 expression levels correlated with treatment response. Further validation in patient samples confirmed the protein's predictive value.
Breast cancer is the most common cancer among women worldwide, with over 2 million new cases diagnosed annually. While advancements in treatment have improved survival rates, response to therapy varies widely among patients. Biomarkers like FGD3 could help address this variability, ensuring patients receive the most effective treatments early.
The study adds to a growing body of research on biomarkers in breast cancer. Other known biomarkers include hormone receptors (ER, PR) and HER2, which guide targeted therapies. However, predictive markers for immunotherapy response remain limited, making FGD3 a potentially valuable addition.
Immunotherapy, which harnesses the immune system to fight cancer, has shown promise in various cancers but has had mixed results in breast cancer. Identifying patients who are likely to respond is crucial for expanding its use. Similarly, chemotherapy, while effective, carries significant toxicity, and biomarkers can help spare non-responders from unnecessary side effects.
The University of Illinois team plans to further validate their findings in larger clinical trials. If confirmed, FGD3 testing could become part of routine diagnostic workup for breast cancer patients. The research was supported by grants from the National Institutes of Health and the American Cancer Society.
The press release was disseminated by TinyGems, a communications platform focusing on innovative small-cap and mid-cap companies. The release notes that TinyGems is part of the Dynamic Brand Portfolio @IBN and provides various services including wire solutions and press release enhancement.
